First Trust Advisors LP Grows Position in Eli Lilly and Company (NYSE:LLY)

First Trust Advisors LP increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 17.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 104,542 shares of the company's stock after purchasing an additional 15,820 shares during the period. First Trust Advisors LP's holdings in Eli Lilly and Company were worth $80,706,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. CWA Asset Management Group LLC boosted its position in Eli Lilly and Company by 11.9% during the fourth quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock worth $5,245,000 after purchasing an additional 724 shares in the last quarter. Centerpoint Advisory Group acquired a new position in Eli Lilly and Company during the fourth quarter worth $514,000. Kentucky Trust Co acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $834,000. Proficio Capital Partners LLC raised its position in shares of Eli Lilly and Company by 30.2% during the 4th quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock worth $5,202,000 after purchasing an additional 1,562 shares during the last quarter. Finally, Cooper Financial Group lifted its stake in Eli Lilly and Company by 35.5% in the 4th quarter. Cooper Financial Group now owns 2,655 shares of the company's stock valued at $2,050,000 after buying an additional 695 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Up 0.4 %

LLY traded up $3.03 on Wednesday, reaching $830.57. The company's stock had a trading volume of 2,712,888 shares, compared to its average volume of 3,427,075. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The stock has a 50 day moving average of $827.10 and a two-hundred day moving average of $818.99. The company has a market capitalization of $787.52 billion, a price-to-earnings ratio of 70.93, a P/E/G ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on LLY shares. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a report on Tuesday. They set an "overweight" rating and a $975.00 target price for the company. Guggenheim reduced their target price on shares of Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research report on Friday, January 17th. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Finally, Wells Fargo & Company increased their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average target price of $1,017.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.